Peak and baseline concentrations of fondaparinux during prophylactic therapy. Results of a prospective investigation under "real life" clinical practice conditions

Phlebologie

Volumn 40, Issue 4, 2011, Pages 187-194

  Schindewolf, Marc ^a   Kanagendran, R ^a   Scheuermann, J ^a   Ackermann, H ^a   Kaufmann, R ^a   Boehncke, W H ^a   Ludwig, R J ^b   Wolf, Z ^a   Lindhoff Last, E ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Department of Trauma and Orthopaedic Surgery   (Germany)

Author keywords

Baseline level; Fondaparinux; Peak level; Pharmacokinetics

Indexed keywords

FONDAPARINUX;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; SKIN ALLERGY; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84860421970     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1621772     Document Type: Article

References (35)

1. Petitou M., Lormeau J.C., Choay J. Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. Nature 1991; 350: 30-33.
2. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S. (Pubitemid 351892971)
3. Harrington R.A., Becker R.C., Cannon C.P. et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 670S-707S. (Pubitemid 351892975)
4. Bauersachs R.M. The CALISTO study [German]. Phlebologie 2011; 40: 79-83.
5. Schindewolf M., Scheuermann J., Beyer-Westendorf J. et al. German Registry for use of fondaparinux in HIT or suspected HIT - preliminary data. Haemostaseologie 2011; 31: A10.
6. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S. (Pubitemid 351892970)
7. Schindewolf M., Scheuermann J., Kroll H. et al. Low allergenic potential with fondaparinux: Results of a prospective investigation. Mayo Clin Proc 2010; 85: 913-919.
8. Schiffner R., Glassl A., Landthaler M., Stolz W. Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids. Contact Dermatitis 2000; 42: 49. (Pubitemid 30052813)
9. Schindewolf M., Schwaner S., Wolter M. et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181: 477-481.
10. Schindewolf M., Kahle B., Lindhoff-Last E., Ludwig R.J. Heparin-induced skin lesions: More common than suspected. Phlebologie 2010; 39: 5-11.
11. Schindewolf M., Ludwig R.J., Wolter M. et al. Diagnosis of heparin-induced delayed-type hypersensitivity. Phlebologie 2010; 39: 226-231.
12. Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
13. Dunn A.S., Spyropoulos A.C., Turpie A.G. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). Thromb Haemost 2007; 5: 2211-2218. (Pubitemid 47617873)
14. Schulman S., Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Thromb Haemost 2005; 3: 692-694. (Pubitemid 41647882)
15. Schulman S., Angeras U., Bergqvist D. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Thromb Haemost 2010; 8: 202-204.
16. Marshall M. Duplex sonography phlebologically accentuated. Phlebologie 2010; 39: 139-151.
17. Warkentin T.E., Linkins L.A. Non-necrotizing heparin-induced skin lesions and the 4T's score. Thromb Haemost 2010; 8: 1483-1485.
18. Bauersachs R.M., Berger K., Hankowitz J. et al. Prophylaxis, diagnosis and therapy of surgery-related complications in orthopedic and trauma surgery. Eur J Trauma 2005; 31: 158-167. (Pubitemid 40655646)
19. Colwell C.W., Jr., Kwong L.M., Turpie A.G., Davidson B.L. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006; 21: 36-45. (Pubitemid 43162983)
20. Warkentin T.E., Maurer B.T., Aster R.H. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
21. Rota E., Bazzan M., Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99: 779-781. (Pubitemid 351694236)
22. Elalamy I., Tribout B. Can heparin-induced thrombocytopenia be associated with fondaparinux use? A rebuttal. Thromb Haemost 2008; 6: 1242-1243; author reply 1243-1246.
23. Damgen-von Brevern G., Klaffling C., Lindhoff-Last E. Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level. Hamostaseologie 2005; 25: 281-285. (Pubitemid 41199743)
24. Decousus H., Prandoni P., Mismetti P. et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 1222-1232.
25. Singelyn F.J., Verheyen C.C., Piovella F. et al. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study. Anesth Analg 2007; 105: 1540-1547. (Pubitemid 350190541)
26. Gogarten W., Van Aken H., Büttner J. et al. Regional anaesthesia and thromboembolism prophylaxis/anticoagulation - Revised recommendations of the German Society of Anaesthesiology and Intensive Care Medicine [German]. Anästh Intensivmed 2007; 48: S109-S124. (Pubitemid 350041414)
27. Hammerstingl C., Omran H., Tripp C., Poetzsch B. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin ? A pilot study. Thromb Haemost 2009; 101: 325-332.
28. Turpie A.G., Lensing A.W., Fuji T., Boyle D.A. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis 2009; 20: 114-121.
29. Donat F., Duret J.P., Santoni A. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl 2: 1-9. (Pubitemid 35155551)
30. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956. (Pubitemid 47393577)
31. Lassen M.R., Ageno W., Borris L.C. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. (Pubitemid 351930852)
32. Cohen A.T., Spiro T.E., Buller H.R. et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31: 407-416.
33. Cohen A.T., Davidson B.L., Gallus A.S. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-329.
34. Handschin A.E., Trentz O.A., Hoerstrup S.P. et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-183. (Pubitemid 40269331)
35. Turpie A., Bauer K., Eriksson B., Lassen M. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003; 90: 364-366. (Pubitemid 36992515)